MedPath

Salbutamol

Generic Name
Salbutamol
Brand Names
Airomir, Airsupra, Combivent, Proair, Proventil, Ventolin
Drug Type
Small Molecule
Chemical Formula
C13H21NO3
CAS Number
18559-94-9
Unique Ingredient Identifier
QF8SVZ843E
Background

Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formulated as a racemic mixture of the R- and S-isomers. The R-isomer has 150 times greater affinity for the beta2-receptor than the S-isomer and the S-isomer has been associated with toxicity. This lead to the development of levalbuterol, the single R-isomer of salbutamol. However, the high cost of levalbuterol compared to salbutamol has deterred wide-spread use of this enantiomerically pure version of the drug. Salbutamol is generally used for acute episodes of bronchospasm caused by bronchial asthma, chronic bronchitis and other chronic bronchopulmonary disorders such as chronic obstructive pulmonary disorder (COPD). It is also used prophylactically for exercise-induced asthma.

Indication

Salbutamol is indicated for (i) the symptomatic relief and prevention of bronchospasm due to bronchial asthma, chronic bronchitis, reversible obstructive airway disease, and other chronic bronchopulmonary disorders in which bronchospasm is a complicating factor, and/or (ii) the acute prophylaxis against exercise-induced bronchospasm and other stimuli known to induce bronchospasm.

Associated Conditions
Asthma, Asthmatic Bronchitis, Bronchial Asthma, Bronchoconstriction, Bronchospasm, Chronic Asthma, Chronic Bronchitis, Cough, Emphysema, Exacerbation of asthma, Exercise-Induced Bronchospasm, Hyperkalemia, Wheezing, Excess mucus or phlegm
Associated Therapies
Airway secretion clearance therapy, Bronchodilation

Efficacy of Intermittent Tiotropium in Early Childhood Wheezing

Phase 4
Completed
Conditions
Wheezing
Obstruction Airway
Wheezy Bronchitis
Asthmatic Bronchitis
Interventions
First Posted Date
2017-06-27
Last Posted Date
2021-02-16
Lead Sponsor
Helsinki University Central Hospital
Target Recruit Count
80
Registration Number
NCT03199976
Locations
🇫🇮

Skin and Allergy Hospital, Helsinki University Hospital, Helsinki, Finland, Helsinki, Finland

A Long-term Safety Study of Fixed Dose Combination Therapy Fluticasone Furoate/Umeclidinium Bromide/Vilanterol Trifenatate in Japanese Subjects With Asthma

Phase 3
Completed
Conditions
Asthma
Interventions
Drug: FF/UMEC/VI 100/62.5/25 mcg
Drug: FF/UMEC/VI 200/62.5/25 mcg
Drug: Salbutamol
Other: ACQ-7
First Posted Date
2017-06-14
Last Posted Date
2020-05-29
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
111
Registration Number
NCT03184987
Locations
🇯🇵

GSK Investigational Site, Toyama, Japan

Reducing Diagnostic Error to Improve Patient Safety in COPD and Asthma (REDEFINE Study)

Phase 3
Completed
Conditions
COPD Asthma
Interventions
Device: Spirometry at initial visit
Drug: Albuterol
Device: Spirometry at 12-month follow-up
First Posted Date
2017-05-02
Last Posted Date
2024-02-26
Lead Sponsor
University of Illinois at Chicago
Target Recruit Count
402
Registration Number
NCT03137303
Locations
🇺🇸

UI Health, Chicago, Illinois, United States

🇺🇸

CCHHS, Chicago, Illinois, United States

In Vivo Investigation of Novel Nano-vesicles of Salbutamol Sulphate

Phase 1
Completed
Conditions
Pulmonary Disease
Drug Effect
Interventions
First Posted Date
2017-02-23
Last Posted Date
2017-02-23
Lead Sponsor
British University In Egypt
Target Recruit Count
20
Registration Number
NCT03059017

Acute Effect of Salbutamol on Heart Rate and Blood Pressure During Exercise in Patients With Moderate or Severe Asthma and Healthy Subjects

Phase 4
Completed
Conditions
Asthma
Heart Rate Fast
Interventions
Drug: Placebo
Drug: salbutamol
First Posted Date
2017-02-07
Last Posted Date
2017-02-07
Lead Sponsor
Universidade Ibirapuera
Target Recruit Count
15
Registration Number
NCT03044938
Locations
🇧🇷

Jaqueline Ribas de Melo, Sao Paulo, São Paulo, Brazil

Beta2-mimetic and Central Nervous System

Not Applicable
Completed
Conditions
Albuterol Effect
Adrenergic Beta-2 Agonist Effect
Interventions
Drug: Placebo
Drug: Salbutamol
First Posted Date
2016-10-05
Last Posted Date
2017-10-02
Lead Sponsor
University Hospital, Grenoble
Target Recruit Count
15
Registration Number
NCT02925130
Locations
🇫🇷

Grenoble University Hospital, Grenoble, France

The Cardiopulmonary Effect of Inhaled Beta-2-agonists on Adult Patients Born With Ventricular Septum Defects.

Phase 4
Completed
Conditions
Ventricular Septal Defect
Interventions
Drug: Salbutamol
Drug: Norflouran (Placebo Evohaler(R) )
First Posted Date
2016-09-26
Last Posted Date
2018-07-05
Lead Sponsor
University of Aarhus
Target Recruit Count
96
Registration Number
NCT02914652
Locations
🇩🇰

Dept. of Cardiothoracic and Vascular Surgery, Aarhus, Denmark

Inhaled Beta-adrenergic Agonists to Treat Pulmonary Vascular Disease in Heart Failure With Preserved EF (BEAT HFpEF): A Randomized Controlled Trial

Phase 3
Completed
Conditions
Heart Failure, Left-Sided
Congestive Heart Failure
Left-Sided Heart Failure
Interventions
Other: Saline placebo
Drug: Albuterol
First Posted Date
2016-08-31
Last Posted Date
2019-02-22
Lead Sponsor
Mayo Clinic
Target Recruit Count
30
Registration Number
NCT02885636
Locations
🇺🇸

Mayo Clinic, Rochester, Minnesota, United States

Measurement of Respiratory Admittance for Pediatric Asthma Diagnosis

Phase 4
Completed
Conditions
Asthma
Interventions
Drug: Salbutamol
Procedure: Forced oscillation technique
Procedure: Plethysmography
First Posted Date
2016-08-24
Last Posted Date
2016-08-24
Lead Sponsor
Central Hospital, Nancy, France
Target Recruit Count
177
Registration Number
NCT02877537
Locations
🇫🇷

CHU de Nancy - Hôpital BRABOIS Enfants - Explorations fonctionnelles pédiatriques, Vandœuvre-lès-Nancy, France

Phase I, Placebo-Controlled, Blinded Pilot Study of Ipratropium in Children Admitted to the ICU With Status Asthmaticus

Phase 1
Completed
Conditions
Status Asthmaticus
Interventions
First Posted Date
2016-08-19
Last Posted Date
2019-04-18
Lead Sponsor
University Hospitals Cleveland Medical Center
Target Recruit Count
30
Registration Number
NCT02872597
Locations
🇺🇸

Rainbow Babies and Children's Hospital (of Univ. Hospitals Case Med. Center), Cleveland, Ohio, United States

© Copyright 2025. All Rights Reserved by MedPath